Research programme: GPCR targeting therapeutics - GIO Therapeutics
Latest Information Update: 04 Mar 2024
At a glance
- Originator GIO Therapeutics
- Class Anti-inflammatories; Antineoplastics
- Mechanism of Action G protein-coupled receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Cancer; Inflammation
Most Recent Events
- 01 Feb 2024 Research programme: GPCR targeting therapeutics - GIO Therapeutics is available for licensing as of 01 Feb 2024. https://www.giotherapeutics.com/#mission
- 01 Feb 2024 Early research in Cancer in Switzerland (unspecified route)
- 01 Feb 2024 Early research in Inflammation in Switzerland (unspecified route)